自身免疫性溶血性贫血治疗进展及适应证选择

付蓉; 于虹

doi:10.13201/j.issn.1004-2806.2023.11.002

自身免疫性溶血性贫血治疗进展及适应证选择

付蓉^1, ,,
于虹¹

- 天津医科大学总医院血液科(天津，300052)

详细信息

作者简介:
专家简介：付蓉，主任医师、教授、博士生导师，天津医科大学总医院副院长，天津市血液系统疾病临床研究中心主任，天津市骨髓衰竭及癌性造血克隆防治重点实验室主任。兼任中华医学会血液学分会常委、中华医学会血液学分会红细胞疾病学组副组长、中国医师协会血液科医师分会常委、中国抗癌协会血液肿瘤专业委员会中国MDS/MPN工作组副组长、天津市医学会血液学分会主委、天津市医师协会血液内科医师分会第一届会长、《中华血液学杂志》副主编。天津市教学名师。主持国家自然科学基金6项，省部级科研项目近10项。获天津市科技进步二等奖4项，获天津市青年科技奖

通讯作者: 付蓉，E-mail：florai@163.com

中图分类号: R556.6

收稿日期: 2023-08-14

刊出日期: 2023-11-01

Progress towards therapies for disease and the choice of indications in autoimmune hemolytic anemia

FU Rong^1, ,,
YU Hong¹

- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, 300052, China

More Information

Corresponding author: FU Rong, E-mail: florai@163.com

Received Date: 14 August 2023

Publish Date: 01 November 2023

摘要

摘要: 自身免疫性溶血性贫血是一组异质性疾病，需要进行全面的实验室检查，以明确诊断并确定亚型后选择治疗方案。无论是初诊还是复发、难治患者，均应全面评估疾病性质及患者体能等以选择合适的治疗药物。目前，最佳治疗方法仍有待探索，多种新型靶向药物已出现，多项临床试验亦在进行，未来会改善难治性自身免疫性溶血性贫血患者的预后，但也将面临如何确定适应证及如何优化使用等多重挑战，以实现从经验到精准的治疗策略转变。
- 溶血性贫血 /
- 治疗 /
- 进展 /
- 适应证
Abstract: Autoimmune hemolytic anemia(AIHA) is a heterogeneous group of diseases that need exact diagnosis of the subtype is required to select the appropriate treatment. For most AIHAs, the choice of optimal therapy remains to be found. Novel agents targeting B-cells, extravascular hemolysis, removing IgG, or complement and prospective clinical trials will make it possible to individualize therapy in the relapsed/refractory settings. Therefore, optimal selection of therapy based on AIHA type, disease profile and patient characteristics will realize a shift from experience to precise treatment strategies in the future.
- hemolytic anemia /
- therapies /
- progress /
- indications

HTML全文

参考文献(31)

[1]	Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting[J]. Blood Rev, 2020, 41: 100648. doi: 10.1016/j.blre.2019.100648
[2]	Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias[J]. N Engl J Med, 2021, 385(15): 1407-1419. doi: 10.1056/NEJMra2033982
[3]	中华医学会血液学分会红细胞疾病(贫血)学组. 中国成人自身免疫性溶血性贫血诊疗指南(2023年版)[J]. 中华血液学杂志, 2023, 44(1): 12-18.
[4]	Yui JC, Brodsky RA. Updates in the Management of Warm Autoimmune Hemolytic Anemia[J]. Hematol Oncol Clin North Am, 2022, 36(2): 325-339. doi: 10.1016/j.hoc.2021.11.005
[5]	Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase Ⅲ randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia[J]. Br J Haematol, 2013, 163(3): 393-399. doi: 10.1111/bjh.12541
[6]	Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults(the RAIHA study)[J]. Am J Hematol, 2017, 92(1): 23-27. doi: 10.1002/ajh.24570
[7]	Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?[J]. Front Immunol, 2023, 24, 14: 1180509.
[8]	Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies[J]. Autoimmun Rev, 2015, 14(4): 304-313. doi: 10.1016/j.autrev.2014.11.014
[9]	Fattizzo B, Zaninoni A, Pettine L, et al. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after[J]. Blood, 2019, 133(9): 996-998. doi: 10.1182/blood-2018-12-885228
[10]	Fu R, Yan S, Wang X, et al. A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults[J]. Int J Hematol, 2016, 104(4): 462-467. doi: 10.1007/s12185-016-2056-5
[11]	Rai MP, Lee EJ, Bussel JB. Maintenence rituximab following induction in autoimmune cytopenias[J]. Br J Haematol, 2023, 202(1): 153-158. doi: 10.1111/bjh.18814
[12]	Maskal S, Al Marzooqi R, Fafaj A, et al. Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia[J]. Surg Endosc, 2022, 36(8): 5863-5872. doi: 10.1007/s00464-022-09116-x
[13]	Hoffmann J, Schliesser G, Neubauer A. Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report[J]. Hematology, 2023, 28(1): 2208010. doi: 10.1080/16078454.2023.2208010
[14]	Fattizzo B, Cantoni S, Giannotta JA, et al. Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers[J]. Ther Adv Hematol, 2022, 13: 20406207221097780.
[15]	Williams O, Bhat R, Badawy SM. Sirolimus for treatment of refractory primary warm autoimmune hemolytic anemia in children[J]. Blood Cells Mol Dis, 2020, 83: 102427. doi: 10.1016/j.bcmd.2020.102427
[16]	付蓉, 于虹. 我如何诊断和治疗自身免疫性溶血性贫血[J]. 中华血液学杂志, 2022, 43(11): 910-915. doi: 10.3760/cma.j.issn.0253-2727.2022.11.005
[17]	付蓉, 邵宗鸿, 刘鸿, 等. 静脉注射免疫球蛋白在治疗自身免疫性溶血性贫血中的作用[J]. 中华内科杂志, 2001, 40(10): 692-693. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHNK200110017.htm
[18]	Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia[J]. Blood, 2021, 137(10): 1283-1294. doi: 10.1182/blood.2019003808
[19]	Piatek CI, Bocian H, Algaze S, et al. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia[J]. Acta Haematol, 2020, 143(3): 244-249. doi: 10.1159/000501538
[20]	方力维, 潘虹, 施均. 伊布替尼治疗复发/难治原发性自身免疫性溶血性贫血二例——探索性研究[J]. 中华血液学杂志, 2020, 41(5): 412-416.
[21]	Kuter DJ, Rogers KA, Boxer MA, et al. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study[J]. Am J Hematol, 2022, 97(6): 691-699. doi: 10.1002/ajh.26508
[22]	Gertz MA. Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia[J]. Hematol Oncol Clin North Am, 2022, 36(2): 341-352. doi: 10.1016/j.hoc.2021.11.001
[23]	Berentsen S. How I treat cold agglutinin disease[J]. Blood, 2021, 137(10): 1295-1303. doi: 10.1182/blood.2019003809
[24]	de Boer ECW, Jalink M, Delvasto-Nuñez L, et al. C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia[J]. Blood Adv, 2023, 7(13): 3128-3139. doi: 10.1182/bloodadvances.2022009402
[25]	Moore DC, Arnall JR. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis[J]. Ann Pharmacother, 2023, 57(8): 970-977. doi: 10.1177/10600280221138802
[26]	Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease(DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial[J]. Blood Adv, 2018, 2(19): 2543-2549. doi: 10.1182/bloodadvances.2018024190
[27]	Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome[J]. Blood, 2021, 138(20): 2002-2005. doi: 10.1182/blood.2021012039
[28]	Jacobs JW, Villalba CAF, Booth GS, et al. Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review[J]. Blood Adv, 2023, 7(11): 2520-2527. doi: 10.1182/bloodadvances.2022009516
[29]	Jackson EM, Harper S, Webb GJ, et al. Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine(BNT162b2 mRNA)managed with emergency splenectomy and complement inhibition with eculizumab[J]. BMJ Case Rep, 2022, 15(8): e250774. doi: 10.1136/bcr-2022-250774
[30]	Fattizzo B, Michel M, Zaninoni A, et al. Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study[J]. Haematologica, 2021, 106(2): 622-625.
[31]	Shiroshita K, Okayama M, Soma H, et al. Thromboembolism Early After Glucocorticoid Administration in Patients with Autoimmune Hemolytic Anemia[J]. Clin Hematol Int, 2023, 5(2-3): 165-169. doi: 10.1007/s44228-023-00043-9